Previsioni

Il prezzo obiettivo medio degli analisti è 75,85 € (+15,08%). La mediana è 79,01 € (+19,88%).

Notizie Vai al feed delle notizie

Kiniksa Pharmaceuticals International names Ross Moat COO and Eben Tessari chief strategy officer

Kiniksa Pharmaceuticals International’s board has appointed Ross Moat as chief operating officer effective Friday; Moat will also remain responsible for commercial activities. Eben Tessari was named chief strategy officer and will continue to lead strategy, business development and technical operations as well as the company’s AI initiatives. Both appointments involve no changes to compensation arrangements; Kiniksa is headquartered in London and trades on Nasdaq under the ticker KNSA. » Altro su de.investing.com

Nell'ultimo trimestre, Kiniksa Pharmaceuticals International PLC Class A ha registrato ricavi pari a 213,44 Mln € e un utile netto di 22,28 Mln €

Metrica	Valore
Capitalizzazione di mercato	5,02 Mld €
Numero di azioni	76,21 Mln
Massimo/minimo a 52 settimane	72,81 € - 30,90 €
Dividendi	No
Beta	0,09
Rapporto P/E	70,17
Rapporto PEG	0,04
Rapporto P/B	8,90
Rapporto P/S	6,80

Nome	Kiniksa Pharmaceuticals International PLC Class A
CEO	Sanj K. Patel
Sede centrale	London, gl Regno Unito
Sito web	kiniksa.com
Settore	Materiali
Industria	Prodotti chimici
Dipendenti	366